Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-01-10

Clinical Trial Update: Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated zoledronic acid for preventing bone loss in postmenopausal women with osteopenia and has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Osteopenia | Phase 3 | Status: COMPLETED | Results posted: 2011-01-10